Is Src the key to understanding metastasis and developing new treatments for colon cancer?

@article{Chen2008IsST,
  title={Is Src the key to understanding metastasis and developing new treatments for colon cancer?},
  author={Jiezhong Chen},
  journal={Nature Clinical Practice Gastroenterology &Hepatology},
  year={2008},
  volume={5},
  pages={306-307}
}
Colon cancer is the fourth most common cancer worldwide and causes half a million deaths each year.1 Colon cancer is treated by surgical resection of the tumor, but in a large proportion of patients the cancer is metastatic and cannot be cured by surgery; in most of these cases the disease carries a survival time from diagnosis of <2 years. Treatments for metastatic colon cancer are, therefore, urgently sought. The proto-oncogene tyrosine-protein kinase Src regulates the activation of cellular… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Colon cancer is the fourth most common cancer worldwide and causes half a million deaths each year.1 Colon cancer is treated by surgical resection of the tumor , but in a large proportion of patients the cancer is metastatic and can not be cured by surgery ; in most of these cases the disease carries a survival time from diagnosis of < 2 years .
Colon cancer is the fourth most common cancer worldwide and causes half a million deaths each year.1 Colon cancer is treated by surgical resection of the tumor , but in a large proportion of patients the cancer is metastatic and can not be cured by surgery ; in most of these cases the disease carries a survival time from diagnosis of < 2 years .
Colon cancer is the fourth most common cancer worldwide and causes half a million deaths each year.1 Colon cancer is treated by surgical resection of the tumor , but in a large proportion of patients the cancer is metastatic and can not be cured by surgery ; in most of these cases the disease carries a survival time from diagnosis of < 2 years .
For example , a mutation that results in constitutively activated Src has been found in 12% of patients with colon cancer.5 For these reasons , I believe that Src is the key to understanding how colon cancer metastasizes , and to potentially developing more effective colon cancer treatments
Colon cancer is the fourth most common cancer worldwide and causes half a million deaths each year.1 Colon cancer is treated by surgical resection of the tumor , but in a large proportion of patients the cancer is metastatic and can not be cured by surgery ; in most of these cases the disease carries a survival time from diagnosis of < 2 years .
Src is already a therapeutic target for inhibitors of its activity : Dasatinib ( Bristol - Myers Squibb , New York , NY ) , AZD0530 ( AstraZeneca , Alderley Park , UK ) , Bosutinib ( Wyeth Cambridge , MA ) , and KXO1(Kinex , Buffalo , NY ) have all been investigated in clinical trials;2 PP1 and PP2 ( Calbiochem , San Diego , CA ) have been investigated only in experimental studies.3,4 Src inhibitors are being investigated because Src is activated in patients with colon cancer and colon cancer metastasis is associated with progressively elevated Src activity.2 Overexpression of a mutated active Src gene , and overexpression of a v - Src gene in mice , have both been shown to promote colon cancer metastasis.5
Src is already a therapeutic target for inhibitors of its activity : Dasatinib ( Bristol - Myers Squibb , New York , NY ) , AZD0530 ( AstraZeneca , Alderley Park , UK ) , Bosutinib ( Wyeth Cambridge , MA ) , and KXO1(Kinex , Buffalo , NY ) have all been investigated in clinical trials;2 PP1 and PP2 ( Calbiochem , San Diego , CA ) have been investigated only in experimental studies.3,4 Src inhibitors are being investigated because Src is activated in patients with colon cancer and colon cancer metastasis is associated with progressively elevated Src activity.2 Overexpression of a mutated active Src gene , and overexpression of a v - Src gene in mice , have both been shown to promote colon cancer metastasis.5
The proto - oncogene tyrosine - protein kinase Src regulates the activation of cellular proteins such as phosphoinositide 3-kinase ( PI3 K ) , protein kinase C , phospholipase and Ras .
The proto - oncogene tyrosine - protein kinase Src regulates the activation of cellular proteins such as phosphoinositide 3-kinase ( PI3 K ) , protein kinase C , phospholipase and Ras .
The proto - oncogene tyrosine - protein kinase Src regulates the activation of cellular proteins such as phosphoinositide 3-kinase ( PI3 K ) , protein kinase C , phospholipase and Ras .
The proto - oncogene tyrosine - protein kinase Src regulates the activation of cellular proteins such as phosphoinositide 3-kinase ( PI3 K ) , protein kinase C , phospholipase and Ras .
Colon cancer is the fourth most common cancer worldwide and causes half a million deaths each year.1 Colon cancer is treated by surgical resection of the tumor , but in a large proportion of patients the cancer is metastatic and can not be cured by surgery ; in most of these cases the disease carries a survival time from diagnosis of < 2 years .
Src is already a therapeutic target for inhibitors of its activity : Dasatinib ( Bristol - Myers Squibb , New York , NY ) , AZD0530 ( AstraZeneca , Alderley Park , UK ) , Bosutinib ( Wyeth Cambridge , MA ) , and KXO1(Kinex , Buffalo , NY ) have all been investigated in clinical trials;2 PP1 and PP2 ( Calbiochem , San Diego , CA ) have been investigated only in experimental studies.3,4 Src inhibitors are being investigated because Src is activated in patients with colon cancer and colon cancer metastasis is associated with progressively elevated Src activity.2 Overexpression of a mutated active Src gene , and overexpression of a v - Src gene in mice , have both been shown to promote colon cancer metastasis.5
Src is already a therapeutic target for inhibitors of its activity : Dasatinib ( Bristol - Myers Squibb , New York , NY ) , AZD0530 ( AstraZeneca , Alderley Park , UK ) , Bosutinib ( Wyeth Cambridge , MA ) , and KXO1(Kinex , Buffalo , NY ) have all been investigated in clinical trials;2 PP1 and PP2 ( Calbiochem , San Diego , CA ) have been investigated only in experimental studies.3,4 Src inhibitors are being investigated because Src is activated in patients with colon cancer and colon cancer metastasis is associated with progressively elevated Src activity.2 Overexpression of a mutated active Src gene , and overexpression of a v - Src gene in mice , have both been shown to promote colon cancer metastasis.5
All Topics